RxDoctor Payments DataLook up a doctor →

David Cotter, MD

Dermatology · Las Vegas, NVNPI 1821482373

Payments from drug & device makers

$1,497,986in general payments, 2019–2025

Across 2,470 payments — averaging $606.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$468K
  • Sanofi$187K
  • Galderma Laboratories, L.p.$140K
  • E.r. Squibb & Sons, L.L.C.$132K
  • LEO Pharma Inc.$102K
  • UCB, Inc.$97K
  • plus $371K from 45 others
$4,137in research payments, 2019–2025

Across 12 payments — averaging $344.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$3K
  • Regeneron$2K

What the payments were for

  • Consulting fees$256,24319%
  • Speaking & faculty fees$982,18271%
  • Travel & lodging$89,8787%
  • Food & beverage$53,0954%
  • Education$1,2430%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,497,986 in reported general payments places this provider in the 95th percentile of 78 dermatology providers in Nevada.

See all dermatology providers in Nevada

Medicare billing

Part B allowed, 2024
$411,019
Medicare patients
506
Services billed
4,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa13$272,626
Dupixent PenDupilumab41$148,594
Cosentyx Sensoready (2 Pens)Secukinumab11$73,798
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc39$1,944
Ketoconazole172$1,835
Clobetasol Propionate41$1,568
Tacrolimus15$1,533
Clindamycin Phosphate54$1,515
Fluocinonide39$1,375
Triamcinolone Acetonide102$1,292
Doxycycline Hyclate58$1,221
ValacyclovirValacyclovir Hcl31$754
Mupirocin86$641
Ammonium Lactate13$630
Gabapentin32$504

Paid to pharmacies, not to this prescriber.

Other dermatology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →